Abstract
Neuroscience research has been revolutionized by the use of recombinant viral vector technology from the basic, preclinical and clinical levels. Currently, multiple recombinant viral vector types are employed with each having its strengths and weaknesses depending on the proposed application. Helper-dependent adenoviral vectors (HdAd) are emerging as ideal viral vectors that solve a major need in the neuroscience field: (1) expression of transgenes that are too large to be packaged by other viral vectors and (2) rapid onset of transgene expression in the absence of cytotoxicity. Here, we describe the methods for large-scale production of HdAd viral vectors for in vivo use with neurospecific transgene expression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hurtado-Lorenzo A, Millan E, Gonzalez-Nicolini V, Suwelack D et al (2004) Differentiation and transcription factor gene therapy in experimental parkinson’s disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration. Mol Ther 10:507–524
Sarac MS, Windeatt S, Castro MG et al (2002) Intrapituitary adenoviral administration of 7B2 can extend life span and reverse endocrinological deficiencies in 7B2 null mice. Endocrinology 143:2314–2323
Xiong W, Goverdhana S et al (2006) Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 80:27–37
Boettcher M, McManus MT (2015) Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell 58:575–585
Crotty S, Pipkin ME (2015) In vivo RNAi screens: concepts and applications. Trends Immunol 36:315–322
Dyawanapelly S, Ghodke SB, Vishwanathan R et al (2014) RNA interference-based therapeutics: molecular platforms for infectious diseases. J Biomed Nanotechnol 10:1998–2037
Sanchez-Rivera FJ, Jacks T (2015) Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15:387–395
Shen H, McHale CM, Smith MT et al (2015) Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9. Mutat Res Rev Mutat Res 764:31–42
Taylor J, Woodcock S (2015) A perspective on the future of high-throughput RNAi screening: will CRISPR cut out the competition or can RNAi help guide the way? J Biomol Screen 20:1040–1051
Montesinos MS, Chen Z, Young SM Jr (2011) pUNISHER: a high-level expression cassette for use with recombinant viral vectors for rapid and long term in vivo neuronal expression in the CNS. J Neurophysiol 106:3230–3244
Tong H, Kopp-Scheinpflug C et al (2013) Protection from noise-induced hearing loss by Kv2.2 potassium currents in the central medial olivocochlear system. J Neurosci 33:9113–9121
Chen Z, Cooper B, Kalla S et al (2013) The Munc13 proteins differentially regulate readily releasable pool dynamics and calcium-dependent recovery at a central synapse. J Neurosci 33:8336–8351
Lentz TB, Gray SJ, Samulski RJ (2012) Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 48:179–188
Cockrell AS, Kafri T (2007) Gene delivery by lentivirus vectors. Mol Biotechnol 36:184–204
Palmer DJ, Ng P (2005) Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther 16:1–16
Brunetti-Pierri N, Ng T et al (2006) Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther 17:391–404
Danthinne X, Imperiale MJ (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7:1707–1714
Muhammad AK, Puntel M et al (2010) Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther 88:204–213
Vetrini F, Ng P (2010) Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2:1886–1917
Palmer DJ, Ng P (2011) Rescue, amplification, and large-scale production of helper-dependent adenoviral vectors. Cold Spring Harb Protoc 2011:857–866
Palmer DJ, Ng P (2011) Characterization of helper-dependent adenoviral vectors. Cold Spring Harb Protoc 2011:867–870
Puntel M, Curtin JF et al (2006) Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum Gene Ther 17:531–544
Toietta G, Pastore L, Cerullo V et al (2002) Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 5:204–210
Bett AJ, Prevec L, Graham FL (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67:5911–5921
Parks RJ, Graham FL (1997) A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 71:3293–3298
Palmer D, Ng P (2003) Improved system for helper-dependent adenoviral vector production. Mol Ther 8:846–852
Parks RJ, Chen L, Anton M et al (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93:13565–13570
Sakhuja K, Reddy PS et al (2003) Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 14:243–254
Ng P, Evelegh C, Cummings D et al (2002) Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system. J Virol 76:4181–4189
Hardy S, Kitamura M, Harris-Stansil T et al (1997) Construction of adenovirus vectors through Cre-lox recombination. J Virol 71:1842–1849
Acknowledgments
This work has been supported by the Max Planck Society, grants from the Michael J. Fox Foundation, and R01 grant from the National Institutes of Health, National Institute on Deafness and Other Communication Disorders (NIDCD) DC014093-01 and National Eye Institute (NEI) R21 awarded to 5R21EY023408 S.M.Y., Jr.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Montesinos, M.S., Satterfield, R., Young, S.M. (2016). Helper-Dependent Adenoviral Vectors and Their Use for Neuroscience Applications. In: Schwartzbach, S., Skalli, O., Schikorski, T. (eds) High-Resolution Imaging of Cellular Proteins. Methods in Molecular Biology, vol 1474. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6352-2_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6352-2_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6350-8
Online ISBN: 978-1-4939-6352-2
eBook Packages: Springer Protocols